2020 ESC Guidelines for the management of adult congenital heart disease
This guideline cites 2 of the 199 landmark trials in our Cardiology register.
- Issued by
- ESC
- Year
- 2020
- Source
- Baumgartner H, De Backer J, et al. Eur Heart J. 2021;42(6):563–645.doi 10.1093/eurheartj/ehaa554
Adult congenital heart disease is the field where the patients outlived the evidence: survivors of childhood surgery now outnumber children with congenital defects, yet almost nothing here has been tested in a randomised trial. The three below are the exceptions — advanced pulmonary vasodilator therapy in Eisenmenger syndrome and in the Fontan circulation — and the rest of the guideline rests on registries and expert consensus.
Eisenmenger syndrome: advanced therapy2
- 2019MAESTROCardiology · PH / ACHD · Eisenmenger syndromeIn 226 patients with Eisenmenger syndrome in WHO functional class II–III, macitentan did not improve 6-minute walk distance compared with placebo.Read →
- 2006BREATHE-5Cardiology · PH / ACHD · Eisenmenger syndromeIn 54 patients with WHO functional class III Eisenmenger syndrome, bosentan lowered pulmonary vascular resistance and improved 6-minute walk distance without worsening systemic oxygen saturation compared with placebo.Read →
Cited landmark trials not yet in the register4
Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.
- 2008BREATHE-5 open-label extension
Sustained bosentan benefit over 40 weeks in Eisenmenger syndrome.
- 2015TEMPO
Bosentan in the Fontan circulation — improved exercise capacity in a small trial.
- 2018APPROACH-IV / Fontan registries
The observational data behind Fontan-failure risk stratification.
- 2005CONCOR / Euro Heart Survey ACHD
The registries that define outcome expectations across congenital lesions.
Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.